Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.52 |
| ▸ | CA2 | P00918 | 10/20 | 0.52 |
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA7 | P43166 | 5/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433099 | 0.87 | CA1 (0.70) | CA1CA2ACHEDRD3DRD2 | |
| SCHEMBL9505624 | 0.84 | CA1 (0.63) | CA1CA2ACHECA12CA7 | |
| SCHEMBL11895489 | 0.84 | CA1 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL26650239 | 0.84 | CA1 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL11896240 | 0.82 | CA1 (0.49) | CA1CA2ACHECA12CA7 | |
| SCHEMBL1590871 | 0.81 | CA1 (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL20791258 | 0.81 | CA1 (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL4641731 | 0.81 | CA1 (0.47) | CA1CA2CA12CA7CA14 | |
| SCHEMBL9851524 | 0.79 | GRM7 (0.59) | CA1CA2NPC1LMNARAB9A | |
| SCHEMBL1591000 | 0.78 | GRM7 (0.43) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-05-17 | — | — | US | disclosed |
| EP-3728248-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-02-02 | — | — | EP | disclosed |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-17 | — | — | US | disclosed |
| WO-2008061006-A1 | SUBSTITUTED INDAN-2-YL, TETRAHYDRONAPHTHALEN-2-YL, OR DIHYDR0-2H-CHR0MEN-3-YL ARYLSULFONAMIDES AND METHODS OF THEIR USE | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | ROCK1, ROCK2, RHOA | CA1 4470/4885CA2 1167/4885ACHE 2165/4885 |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | CA1 4470/4885CA2 1167/4885ACHE 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.